PHAT is now targeting 25-34 according to analysts. I am not surprised. It has a pipeline and
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech and pharma but this one is far to promising
with the great upside it presents. I will hit this one hard trying to get the low of day in
pieces and build a position.
is pending approval for a medication product to treat a stomach bacteria that causes chronic
infection and symptoms are often refractory to long and elaborate treatment protocols. The
product is already in Asia and doing well in YoY reports. PHAT has partnered with another
pharma company to make regulatory and marketing inroads in the European market. My
portfolio is already heavy with medtech and pharma but this one is far to promising
with the great upside it presents. I will hit this one hard trying to get the low of day in
pieces and build a position.
ملاحظة
NEWS and Analysis seekingalpha.com/article/4480460-phathom-pharmaceuticals-phat-undiscovered-gemملاحظة
Investor Relations investors.phathompharma.com/
ملاحظة
Science phathompharma.com/our-science/ملاحظة
Back up the truck and tell your friends you would like to borrow their truck for a day or two .....ملاحظة
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.